2019 American Transplant Congress
mTOR Inhibitors Associated with Higher Cardiovascular Adverse Events – A Large Population Database Analysis
*Purpose: Our study aimed to compare the adverse events (AEs) of tacrolimus to mammalian target of rapamycin (mTOR) inhibitors in solid organ transplant patients.*Methods: Our…2019 American Transplant Congress
Different Options Available For Patients Registered In A Kidney Paired Donation (KPD) Program
University of Toledo, Toledo, OH
*Purpose: We examined what happened during a 6-year period to 1,121 end-stage renal disease patients who registered with their willing/incompatible living donors for kidney exchanges…2019 American Transplant Congress
Introduction of Universal Hepatitis E RNA Screening in Deceased Organ Donors – The UK Experience
*Purpose: We aim to describe the strategy and initial results of post-donation, universal screening of deceased organ donors in the UK. HEV RNA is tested…2019 American Transplant Congress
C1 Esterase Inhibitor (C1INH) Treatment at Kidney Transplant Improves Long-Term Outcomes in Patients at Risk for Ischemia/Reperfusion Injury & Delayed Graft Function
*Purpose: Delayed graft function(DGF) is defined as need for dialysis early post-transplant. DGF is related to ischemia reperfusion injury (IRI) that diminishes allograft function and…2019 American Transplant Congress
Kidney Allograft Survival Among Kidney-pancreas Recipients Compared To Solitary Kidney Recipients: A Mate Analysis Of The Unos/optn Database
1Hartford Hospital, Hartford, CT, 2Surgery, University of Minnesota, Minneapolis, MN
*Purpose: Deceased donor kidney allocation policies differ between solitary organs and combined transplants. The estimated waiting time for a kidney as part of a simultaneous…2019 American Transplant Congress
Variable Outcomes of Recurrent Autoimmune Diabetes Post Pancreas Transplant Treated with Rituximab
Washington University, St. Louis, MO
*Purpose: Demonstrate the outcomes of treatment with rituximab in patients with autoimmune diabetes after pancreas transplant.*Methods: We present the treatment response to rituximab in 3…2019 American Transplant Congress
Developing a Patient Reported Outcome Measure for Assessment of Calcineurin Inhibitor-Related Symptoms
1Terasaki Research Institute, Los Angeles, CA, 2Bristol Myers Squibb, Princeton, NJ
*Purpose: Calcineurin inhibitor (CNI) therapy has side effects which can potentially impact a patient’s health related quality of life (HRQoL). A standardized measure to assess…2019 American Transplant Congress
Caregiving in Thoracic Transplantation–A SR/MA
*Purpose: Caregivers are required for heart and lung transplantation, however, little emphasis is placed on the pre-transplant caregiving experience. Our objective was to perform a…2019 American Transplant Congress
Post-Transplant Lymphoproliferative Disorders after Living-Donor Liver Transplantation: A Retrospective Cohort Study in 1,900 Cases of Single Center Experience
*Purpose: Post-transplant lymphoproliferative disorders (PTLD) is relatively rare but the most common, life-threatening neoplasms after organ transplantation. Because of their heterogeneity from benign to malignant…2019 American Transplant Congress
Identification of Adult Liver Transplant Recipients Eligible to Participate in an Immunosuppression Withdrawal Trial Employing Non-Invasive Assessments of Allograft Status
*Purpose: Liver Immunosuppression Free Trial (LIFT) is a multicentre international prospective randomised controlled trial of biomarker-guided immunosuppression withdrawal in adult liver transplant recipients who meet…
- « Previous Page
- 1
- …
- 144
- 145
- 146
- 147
- 148
- …
- 214
- Next Page »